Skip to main content

DaVita plays down Ozempic’s potential in treating kidney disease

Dialysis company DaVita is not convinced a Novo Nordisk trial's findings relating to its Ozempic treatment will be borne out over time.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.